Oramed Pharmaceuticals Inc. (TLV:ORMP)

Oramed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Aug 31, 2021
Revenue	-	1.34	2.7	2.71	2.7
Revenue Growth (YoY)	-	-50.42%	-0.33%	0.33%	-0.33%
Gross Profit	-	1.34	2.7	2.71	2.7
Selling, General & Admin	6.46	8.14	15.66	12.58	5.94
Research & Development	6.32	8.97	27.64	27.11	20.99
Operating Expenses	12.78	17.11	43.3	39.69	26.93
Operating Income	-12.78	-15.77	-40.6	-36.98	-24.22
Interest Expense	-0.85	-2.04	-	-	-
Interest & Investment Income	5	8.17	3.57	0.47	0.35
Currency Exchange Gain (Loss)	0.17	-0.12	0.18	-0.03	-0
Other Non Operating Income (Expenses)	-0.04	-1.54	-0.01	-0.01	-0.01
EBT Excluding Unusual Items	-8.5	-11.3	-36.86	-36.55	-23.88
Gain (Loss) on Sale of Investments	-7.42	16.39	-0.81	-0.22	0.9
Pretax Income	-15.92	5.09	-37.66	-36.77	-22.99
Income Tax Expense	3.18	-	0.1	-	-
Earnings From Continuing Operations	-19.1	5.09	-37.76	-36.77	-22.99
Minority Interest in Earnings	0.04	0.44	1.2	1.76	0.75
Net Income	-19.06	5.53	-36.56	-35	-22.24
Net Income to Common	-19.06	5.53	-36.56	-35	-22.24
Shares Outstanding (Basic)	41	40	39	37	28
Shares Outstanding (Diluted)	41	41	39	37	28
Shares Change (YoY)	0.65%	4.02%	5.08%	30.36%	16.71%
EPS (Basic)	-0.47	0.14	-0.94	-0.94	-0.78
EPS (Diluted)	-0.48	0.14	-0.94	-0.94	-0.78
Free Cash Flow	-8.43	-10.55	-28.41	-33.39	-21.56
Free Cash Flow Per Share	-0.21	-0.26	-0.73	-0.90	-0.76
Gross Margin	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-1176.79%	-1501.96%	-1363.50%	-896.15%
Profit Margin	-	412.31%	-1352.61%	-1290.71%	-822.72%
Free Cash Flow Margin	-	-787.24%	-1051.20%	-1231.31%	-797.48%
EBITDA	-12.59	-15.57	-40.54	-36.92	-24.15
D&A For EBITDA	0.19	0.2	0.06	0.05	0.08
EBIT	-12.78	-15.77	-40.6	-36.98	-24.22

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.